NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date (Descending) | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
60505-6113-06 | 60505-6113 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6114-00 | 60505-6114 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6115-02 | 60505-6115 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
00009-0796-01 | 00009-0796 | Methylprednisolone Sodium Succinate | Solu-Medrol | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | April 2, 1959 | Jan. 31, 2021 | No Longer Used | ||
00051-0022-21 | 00051-0022 | Dronabinol | Marinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | July 13, 2010 | Jan. 31, 2021 | No Longer Used |
60505-3877-03 | 60505-3877 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 25, 2015 | Jan. 31, 2021 | No Longer Used |
60505-3877-09 | 60505-3877 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 25, 2015 | Jan. 31, 2021 | No Longer Used |
43063-0560-02 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 4, 2016 | Jan. 18, 2021 | No Longer Used |
43063-0560-03 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 4, 2016 | Jan. 18, 2021 | No Longer Used |
43063-0560-04 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 4, 2016 | Jan. 18, 2021 | No Longer Used |
43063-0560-05 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 12, 2015 | Jan. 18, 2021 | No Longer Used |
43063-0560-06 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 12, 2015 | Jan. 18, 2021 | No Longer Used |
43063-0560-10 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 12, 2015 | Jan. 18, 2021 | No Longer Used |
43063-0560-20 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 12, 2015 | Jan. 18, 2021 | No Longer Used |
59630-0222-07 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | July 5, 2018 | Dec. 31, 2020 | No Longer Used | |
59630-0222-30 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | July 5, 2018 | Dec. 31, 2020 | No Longer Used | |
59630-0222-90 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | July 5, 2018 | Dec. 31, 2020 | No Longer Used | |
00006-0464-05 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | Dec. 31, 2020 | In Use |
00006-0464-10 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | Dec. 31, 2020 | In Use |
60429-0925-90 | 60429-0925 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec. 30, 2016 | Dec. 31, 2020 | No Longer Used |
25021-0814-67 | 25021-0814 | Leucovorin Calcium | Leucovorin Calcium | 100.0 mg/10mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Dec. 1, 2013 | Dec. 31, 2020 | In Use |
63187-0657-30 | 63187-0657 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 1, 2018 | Dec. 31, 2020 | In Use |
63187-0657-60 | 63187-0657 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 1, 2018 | Dec. 31, 2020 | In Use |
63187-0657-90 | 63187-0657 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 1, 2018 | Dec. 31, 2020 | In Use |
00781-5238-06 | 00781-5238 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 19, 2011 | Dec. 31, 2020 | In Use |
Found 10,000 results in 4 milliseconds — Export these results